« Return to News | Drug Sponsors

Immune Pharmaceuticals, EpiCept complete merger

Monday, August 26, 2013 12:15 PM

Immune Pharmaceuticals has completed its merger with EpiCept. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early-stage cancer program and its late-stage topical pain product, AmiKet.

Iin connection with the closing of the merger, the composition of the company's board of directors has increased to seven. Daniel Teper, chief executive officer, has joined the board of directors as chairman.  David Sidransky, professor of oncology at the Johns Hopkins School of Medicine, has been appointed vice chairman.  Ana Stancic has been named the chairperson of the audit committee. Isaac Kobrin, Herve de Kergrohen and Pierre Albouy also have been named to the company's board. 

Robert Cook, EpiCept's previous interim president and chief executive officer, retains his position on the board and has been named chief financial officer. Alan Dunton, previous non-executive chairman of EpiCept, Robert Savage and Keith Brownlie have resigned their positions.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.